Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05990920 · ClinicalTrials.gov registry record · Phase 1
Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy
A Phase 1 study, sponsored by NKGen Biotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05990920 is a Phase 1 study that has completed, run by NKGen Biotech. The registered enrollment target is 6 participants.
The verdict
NCT05990920, a Phase 1 study, has completed, sponsored by NKGen Biotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test SNK02 in participants with pathologically confirmed cancer that is refractory to conventional therapy. The main questions it aims to answer are: * Is SNK02 safety and tolerable when administered weekly as an intravenous infusion * What is the maximum dose that is tolerated of SNK02 Participants will be administered SNK02 weekly for 8 weeks and undergo medical evaluation to provide initial clinical safety data for the treatment of cancer with allogeneic NK cells as a monotherapy treatment.
Interventions
- BIOLOGICAL SNK02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-08-23 |
| Est. Completion | 2024-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05990920
The ClinicalTrials.gov registry entry for NCT05990920 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NKGen Biotech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SNK02 is the first listed.
NCT05990920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05990920 about?
NCT05990920 is a clinical study titled "Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy". The goal of this clinical trial is to test SNK02 in participants with pathologically confirmed cancer that is refractory to conventional therapy. The main questions it aims to answer are: * Is SNK02 safety and tolerable when administered weekly as an intravenous infusion * What is the maximum dose ...
What is the current status of trial NCT05990920?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2023-08-23. Estimated completion is 2024-04-12.
What interventions are being tested in trial NCT05990920?
The interventions under investigation include: SNK02 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05990920?
This trial is sponsored by NKGen Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.